ATNF (180 Life Sciences) 5-Year Yield-on-Cost % : 0.00 (As of Apr. 22, 2025)

View and export this data going back to 2017. Start your Free Trial

What is 180 Life Sciences 5-Year Yield-on-Cost %?

180 Life Sciences's yield on cost for the quarter that ended in Dec. 2024 was 0.00.

The historical rank and industry rank for 180 Life Sciences's 5-Year Yield-on-Cost % or its related term are showing as below:

ATNF's 5-Year Yield-on-Cost % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.66
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of 180 Life Sciences's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, 180 Life Sciences's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

180 Life Sciences's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 180 Life Sciences's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where 180 Life Sciences's 5-Year Yield-on-Cost % falls into.

Save Embed

;

Save Embed

;

180 Life Sciences 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of 180 Life Sciences is calculated as

Yield-on-Cost

Dividend Yield %

Dividend Growth Rate)^5

180 Life Sciences (NAS:ATNF) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

180 Life Sciences 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of 180 Life Sciences's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.

180 Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 180 Life Sciences Corp (NAS:ATNF) » Definitions » 5-Year Yield-on-Cost %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3000 El Camino Real, Building 4, Suite 200, Palo Alto, CA, USA, 94306

Website

https://www.180lifesciences.com

180 Life Sciences Corp was formed as a clinical-stage biotechnology company, focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation, and fibrosis by employing research, and, where appropriate, combination therapy. In addition, it has acquired certain source code and intellectual property relating to the back-end technology platform to operate an online blockchain casino, and moving forward, it plans to focus the majority of its operations on the creation of the online blockchain casino, while looking to monetize certain prior development-stage therapeutic product candidates for unmet medical needs. It has one reportable operating segment, iGaming.

Executives

James N. Woody	director, officer: Chief Executive Officer	C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Marc Feldmann	director	5 DURHAM TERRACE, LONDON X0 W25PB
Lawrence Steinman	director	10555 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Mcgovern Jr. Donald A.	director	C/O CARS.COM, 300 S. RIVERSIDE PLAZA, SUITE 1000, CHICAGO IL 60606
Quan Anh Vu	officer: COO / Chief Business Officer	22616 ERWIN STREET, WOODLAND HILLS CA 91367
Ozan Pamir	officer: Interim CFO	2443 FILLMORE ST #380-17649, SAN FRANCISCO CA 94115
Pamela G Marrone	director	C/O MARRONE BIO INNOVATIONS, INC., 2121 SECOND STREET, A-107, DAVIS CA 95618
Teresa Deluca	director	40 BURTON HILLS BOULEVARD, SUITE 500, NASHVILLE TN 37215
Russell T Ray	director	2525 DUPONT DR, IRVINE CA 92612
Knuettel Ii Francis	director	205 NEWBURY ST, SUITE 204, FRAMINGHAM MA 01701
Marlene Krauss	director, 10 percent owner, officer: Chief Executive Officer	C/O KBL HEALTHCARE INC, 645 MADISON AVE, NEW YORK NY 10022
Lawrence Marshall Gold	director	830 MENLO AVENUE, SUITE 100, MENLO PARK CA 94025
Jonathan B. Rothbard	officer: Chief Scientific Officer	501 BEALE STREET, UNIT 8D, SAN FRANCISCO CA 94105
Shoshana Shendelman	director	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Richard W Barker	director	290 COMMONWEALTH AVENUE #17, BOSTON MA 02115